What precautions should I take while taking Capmatinib?

Capmatinib is a small molecule kinase inhibitor targeting c-Met, which is a receptor tyrosine kinase that activates signaling cascades involved in organ regeneration and tissue repair in healthy humans. Capmatinibis indicated for the treatment of patients with non-small cell lung cancer whose tumor mutations lead to mesenchymal epithelial transition (MET) exon 14 skipping.

1.Interstitial lung disease (ILD)/Pneumonia. A patient treated withcapmatinib developed fatalILD/pneumonitis. Monitor for new or worsening symptoms of ILD/pneumonia (e.g., difficulty breathing, cough, fever). For patients with suspected ILD/pneumonia, discontinue this product immediately, or permanently if no other potential causes of ILD/pneumonia are found.

2.Hepatotoxicity. Hepatotoxicity occurred in patients receivingcapmatinib . Before starting capmatinib, monitor liver function tests (including ALT, AST, and total bilirubin), then monitor monthly or as clinically indicated, with more frequent testing in patients with elevated transaminases or bilirubin. Depending on the severity of the adverse reaction, discontinue use, reduce the dose, or permanently discontinue capmatinib.

3.Pancreatic toxicity. Patients receivingcapmatinibhad elevated amylase and lipase levels. Monitor baseline amylase and lipase periodically during treatment withcapmatinib. Depending on the severity of the adverse reaction, temporarily discontinue, reduce the dose, or permanently discontinue this product.

4.Allergic reaction. Receivedcapmatinib in clinical trials other thanGEOMETRY mono-1Treated patients experienced severe allergic reactions. Signs and symptoms of hypersensitivity reactions include fever, chills, itching, rash, drop in blood pressure, nausea, and vomiting. Depending on the severity of the adverse reaction, capmatinib may be temporarily or permanently discontinued.

5.Photosensitivity risk. Based on animal studies, this product has a potential risk of photosensitivity reactions. In GEOMETRY mono-1, patients are advised to take steps to prevent UV exposure, such as using sunscreen or protective clothing, and are advised to limit direct UV exposure during treatment with capmatinib.

6.Embryo-Fetal Toxicity. Based on the results of animal studies and its mechanism of action, this product can cause harm to the fetus when taken by pregnant women. The exposure to malformations caused by oral capmatinib to pregnant rats and rabbits during organogenesis was lower than that in humans, based on the area under the curve (AUC) at the clinical dose of 400 mgtwice daily. Inform pregnant women of the potential risk to the fetus and recommend that women of childbearing potential use effective contraception duringcapmatinib treatment and for 1 weeks after the last dose,men of childbearing potential who have a female partner are advised to use effective contraception during treatment with capmatiniband for 1weeks after the last dose. There are officially marketed generic drugs in Laos, and each box costs about 3 about 3,000. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.

xa0